iScience (Nov 2022)

Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity

  • Akiho Yoshida,
  • Shinya Okamura,
  • Shiho Torii,
  • Sayuri Komatsu,
  • Paola Miyazato,
  • Hitomi Sasaki,
  • Shiori Ueno,
  • Hidehiko Suzuki,
  • Wataru Kamitani,
  • Chikako Ono,
  • Yoshiharu Matsuura,
  • Shiro Takekawa,
  • Koichi Yamanishi,
  • Hirotaka Ebina

Journal volume & issue
Vol. 25, no. 11
p. 105412

Abstract

Read online

Summary: Live-attenuated vaccines are generally highly effective. Here, we aimed to develop one against SARS-CoV-2, based on the identification of three types of temperature-sensitive (TS) strains with mutations in nonstructural proteins (nsp), impaired proliferation at 37°C–39°C, and the capacity to induce protective immunity in Syrian hamsters. To develop a live-attenuated vaccine, we generated a virus that combined all these TS-associated mutations (rTS-all), which showed a robust TS phenotype in vitro and high attenuation in vivo. The vaccine induced an effective cross-reactive immune response and protected hamsters against homologous or heterologous viral challenges. Importantly, rTS-all rarely reverted to the wild-type phenotype. By combining these mutations with an Omicron spike protein to construct a recombinant virus, protection against the Omicron strain was obtained. We show that immediate and effective live-attenuated vaccine candidates against SARS-CoV-2 variants may be developed using rTS-all as a backbone to incorporate the spike protein of the variants.

Keywords